No. of Recommendations: 6
Pfizer is paying $43 billion to acquire Soligen.
'Seagen expects to generate approximately $2.2 billion of revenue in 2023, representing 12% year-over-year growth, from its four in-line medicines, royalties and collaboration and license agreements. When combining the expected strong growth trajectories for these medicines with candidates that could emerge from Seagen's pipeline, subject to clinical trial and regulatory success, Pfizer believes Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with potential significant growth beyond 2030.'
pfizer.com - Pfizer invests billion battle cancerSo Pfizer is paying 20 times 2023 sales or 4.3 times possible 2030 sales to 'invest' in battling cancer. PFE itself trades for 2.4 EV to TTM sales and 3.4 times forward sales.
Looks their own R&D can't deliver, so they have to repeatedly 'invest' in costlier acquisitions.
seekingalpha.com - Pfizer buys seagen deal may not please shareholders 